Analysis: Chinese pharma giant facing US ban may redirect investment to Ireland

Companies part of the WuXi group that face restrictions by US lawmakers have invested more than €500 million into Ireland in the past five years

Market analysts have warned that firms such as WuXi now face an uncertain future in the US market as the laws would not only ban federal agencies from doing business with WuXi

Earlier this year, US lawmakers set down a marker when they unveiled plans to ban federal agencies from doing business with a number of healthcare firms over alleged ties to the Chinese military.

The Biosecurity Act has cast doubt over the future of several firms in the US, including WuXi Biologics and WuXi AppTec, two sister firms that have spent more than €500 million in recent years expanding operations in Ireland and which employ more ...